Defining activity and patient selection of a novel CDK7 inhibitor, GTAEXS-617, through AI-supported primary cancer tissue profiling. (October 2022) - Somlyay, M.; Durinikova, E.; Besnard, J.; Barbeau, O.; Le Coz, J.; Senekowitsch, M.; Ergüner, B.; Hackner, K.; Dzurillova, L.; Petru, E.; Lafleur, J.; Singer, J.; et al.